MedElevator Войти в исследования
← Поиск публикаций
Медицинская библиотека · Neuro-oncology · 2018

P01.113 Increasing TTFields dose to the tumor bed improves overall survival in newly diagnosed glioblastoma patients

Ballo M, Bomzon Z, Urman N, Lavy-Shahaf G, Toms S

Перевод в очереди

Аннотация

Abstract Background It has been hypothesized that increasing Tumor Treating Fields (TTFields) dose to the tumor leads to better patient outcome. However, to date, this hypothesis has not been demonstrated using clinical data. Here we present a simulation based study testing this hypothesis. The study was performed utilizing data collected during the pivotal EF-14 trial that demonstrated the clinical benefit of combining TTFields with chemoradiation in newly diagnosed Glioblastoma patients. Materials and Methods Patient treated with TTFields for at least 2 months as part of the EF-14 trial ere included in the study. In addition, patients for whom the quality of the MRIs at baseline was insufficient for creation of computational models excluded, leaving n=317 cases. Realistic computational models of these patients were created. The transducer array layouts assigned to the patients, their average monthly compliance (fraction of time patient was on active treatment), and the average electrical current delivered to each patient (calculated from log files of the TTFields generators) were derived. These data were combined into numerical simulations, which yielded an estimate of the TTFields distribution within all patients. During treatment TTFields are delivered in two roughly orthogonal directions by two pairs of transducer arrays. To combine the two roughly orthogonal fields into a single measure of dose, we defined the Local Minimum Dose Density (LMiDD) as the lower of the power densities delivered by the two fields to each point in the model, multiplied by the average compliance of the patient. For each patient, average LMiDD within a tumor bed combining the Gross Tumor Volume and a Peritumoral Boundary Zone 3 mm wide was calculated. To test the hypothesis that maximizing TTFields dose at the tumor beds improves patients’ outcome, they were divided into two groups based on a threshold value of average LMiDD within the tumor bed that yielded the most statistically significant difference in median OS between the groups. Results The optimal threshold of average LMiDD within the tumor bed was found to equal 1.6 MmW/cm3. Splitting the population using this threshold resulted in two groups with similar demographics. OS and PFS were significantly higher in the group that received higher doses of TTFields (OS: 25.1 months vs. 20.9 months, p=0.002, HR=0.69; PFS: 8.8 months vs. 6.5 months, p=0.006 HR=0.66). In addition the median OS and PFS were longer with TTFields when average electric field in the tumor bed was >1.05 V/cm OS (25.0 months vs. 21.6 months, p=0.043, HR=0.76) and PFS (8.1 months vs. 7.9 months, p=0.006 HR=0.74). Conclusions This study is the first to demonstrate a connection between TTFields dose and efficacy in a clinical setting. This study emphasizes the importance of TTFields treatment planning for improving patients’ outcome.

Для цитирования: Ballo M, Bomzon Z, Urman N, Lavy-Shahaf G, Toms S. P01.113 Increasing TTFields dose to the tumor bed improves overall survival in newly diagnosed glioblastoma patients. Neuro-oncology. 2018.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.